EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC 4.0

Population Pharmacokinetic/Pharmacodynamic Modeling of Donidalorsen, an Antisense Oligonucleotide in Development for Prophylaxis of Hereditary Angioedema

John K Diep iD, Miao Liu, Pratap Singh, Steve Dorow, Danny M Cohn iD, Laura Bordone, Kenneth B Newman, Xiang Gao

CPT: Pharmacometrics & Systems Pharmacology · 2026

DOI: 10.1002/psp4.70206 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2026. Verfasst von John K Diep und 7 weiteren Autor:innen. Beteiligte Einrichtung: Ionis, Carlsbad, California, USA. Hauptthemen laut MEDLINE: Angioedemas, Hereditary, Models, Biological, Oligonucleotides, Antisense, Prekallikrein. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ionis Pharmaceuticals, Inc., Ionis Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hereditary angioedema (HAE) is a rare disorder linked to kallikrein‐kinin system dysregulation, which leads to uncontrolled activation of plasma prekallikrein. Donidalorsen is an antisense oligonucleotide designed to selectively degrade prekallikrein messenger RNA and thereby reduce prekallikrein production. We aimed to develop population pharmacokinetic and pharmacokinetic/pharmacodynamic models of donidalorsen and evaluate the impact of potential intrinsic/extrinsic covariates on exposure and prekallikrein response. Plasma donidalorsen and prekallikrein data were obtained from phase 1 to 3 studies in healthy volunteers (NCT03263507, 721744‐CS9) and adult and adolescent patients with HAE (NCT04030598, NCT05139810). The evaluated doses were 20, 40, 60, and 80 mg every 4 weeks (Q4W) and 80 mg every 8 weeks (Q8W), administered subcutaneously over 13–21 weeks. Donidalorsen pharmacokinetics were well described by a linear 2‐compartment model with first‐order absorption. The population terminal elimination half‐life was 31.4 days. Prekallikrein was well described by an indirect response model with inhibition of prekallikrein production by donidalorsen. Covariate analysis identified body weight as the main factor affecting pharmacokinetic exposure; however, this effect was not considered clinically significant. The developed population pharmacokinetic/pharmacodynamic model well characterized the donidalorsen exposure–prekallikrein response relationship. Modeling analyses support that no dose adjustment is needed with respect to intrinsic/extrinsic factors in adults and adolescents with HAE. The nearly identical simulated pharmacokinetic or prekallikrein time courses for Q4W versus monthly dosing and for Q8W versus every‐2‐month dosing regimens support switching to more convenient regimens for patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angioedemas, HereditaryModels, BiologicalOligonucleotides, AntisensePrekallikreinAdolescentAdultFemaleHumansMaleMiddle AgedYoung AdultDose-Response Relationship, DrugOligonucleotides

Stichwörter der Autor:innen

GalNAcantisense oligonucleotidedonidalorsenhereditary angioedemamodel‐based drug developmentpharmacometricspopulation pharmacokinetics‐pharmacodynamicsprophylactic

Substanzen

donidalorsenOligonucleotides, AntisensePrekallikreinOligonucleotides

Autor:innen und Institutionen

  • Ionis, Carlsbad, California, USA.
  • Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.

ORCID-Profile: John K Diep, Danny M Cohn

Förderung

  • Ionis Pharmaceuticals, Inc.
  • Ionis Pharmaceuticals

Zitieren

APA

Diep, J. K., Liu, M., Singh, P., Dorow, S., Cohn, D. M., Bordone, L., Newman, K. B., & Gao, X. (2026). Population Pharmacokinetic/Pharmacodynamic Modeling of Donidalorsen, an Antisense Oligonucleotide in Development for Prophylaxis of Hereditary Angioedema. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.70206

Vancouver

Diep JK, Liu M, Singh P, Dorow S, Cohn DM, Bordone L, et al. Population Pharmacokinetic/Pharmacodynamic Modeling of Donidalorsen, an Antisense Oligonucleotide in Development for Prophylaxis of Hereditary Angioedema. CPT: Pharmacometrics & Systems Pharmacology. 2026. doi:10.1002/psp4.70206

BibTeX
@article{Diep2026,
  author = {Diep, John K and Liu, Miao and Singh, Pratap and Dorow, Steve and Cohn, Danny M and Bordone, Laura and Newman, Kenneth B and Gao, Xiang},
  title = {Population Pharmacokinetic/Pharmacodynamic Modeling of Donidalorsen, an Antisense Oligonucleotide in Development for Prophylaxis of Hereditary Angioedema},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2026},
  doi = {10.1002/psp4.70206}
}
Kostenlos starten →